vs
REGIS CORP（RGS）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
REGIS CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.6倍（$57.1M vs $35.5M），REGIS CORP净利率更高（0.8% vs -304.2%，领先305.0%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 22.3%），REGIS CORP自由现金流更多（$891.0K vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 7.8%）
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
RGS vs RXRX — 直观对比
营收规模更大
RGS
是对方的1.6倍
$35.5M
营收增速更快
RXRX
高出659.5%
22.3%
净利率更高
RGS
高出305.0%
-304.2%
自由现金流更多
RGS
多$48.2M
$-47.3M
两年增速更快
RXRX
近两年复合增速
7.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.1M | $35.5M |
| 净利润 | $456.0K | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 10.8% | -304.8% |
| 净利率 | 0.8% | -304.2% |
| 营收同比 | 22.3% | 681.7% |
| 净利润同比 | -94.0% | 39.6% |
| 每股收益（稀释后） | $0.16 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGSRXRX
| Q4 25 | $57.1M | $35.5M | ||
| Q3 25 | $59.0M | $5.2M | ||
| Q2 25 | $60.4M | $19.2M | ||
| Q1 25 | $57.0M | $14.7M | ||
| Q4 24 | $46.7M | $4.5M | ||
| Q3 24 | $46.1M | $26.1M | ||
| Q2 24 | $49.4M | $14.4M | ||
| Q1 24 | $49.2M | $13.8M |
净利润RGSRXRX
| Q4 25 | $456.0K | $-108.1M | ||
| Q3 25 | $1.4M | $-162.3M | ||
| Q2 25 | $116.5M | $-171.9M | ||
| Q1 25 | $250.0K | $-202.5M | ||
| Q4 24 | $7.6M | $-178.9M | ||
| Q3 24 | $-853.0K | $-95.8M | ||
| Q2 24 | $91.2M | $-97.5M | ||
| Q1 24 | $-2.3M | $-91.4M |
毛利率RGSRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率RGSRXRX
| Q4 25 | 10.8% | -304.8% | ||
| Q3 25 | 10.0% | -3327.6% | ||
| Q2 25 | 12.1% | -916.8% | ||
| Q1 25 | 8.8% | -1297.9% | ||
| Q4 24 | 11.8% | -4042.4% | ||
| Q3 24 | 4.6% | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | 8.3% | -698.4% |
净利率RGSRXRX
| Q4 25 | 0.8% | -304.2% | ||
| Q3 25 | 2.3% | -3135.3% | ||
| Q2 25 | 192.9% | -894.2% | ||
| Q1 25 | 0.4% | -1373.3% | ||
| Q4 24 | 16.4% | -3935.5% | ||
| Q3 24 | -1.9% | -367.5% | ||
| Q2 24 | 184.7% | -676.6% | ||
| Q1 24 | -4.7% | -662.4% |
每股收益（稀释后）RGSRXRX
| Q4 25 | $0.16 | $-0.17 | ||
| Q3 25 | $0.49 | $-0.36 | ||
| Q2 25 | $43.67 | $-0.41 | ||
| Q1 25 | $0.08 | $-0.50 | ||
| Q4 24 | $2.71 | $-0.56 | ||
| Q3 24 | $-0.36 | $-0.34 | ||
| Q2 24 | $38.40 | $-0.40 | ||
| Q1 24 | $-1.00 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.4M | $743.3M |
| 总债务越低越好 | $113.3M | $9.6M |
| 股东权益账面价值 | $188.7M | $1.1B |
| 总资产 | $588.3M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.60× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资RGSRXRX
| Q4 25 | $18.4M | $743.3M | ||
| Q3 25 | $16.6M | $659.8M | ||
| Q2 25 | $17.0M | $525.1M | ||
| Q1 25 | $13.3M | $500.5M | ||
| Q4 24 | $10.2M | $594.4M | ||
| Q3 24 | $6.3M | $427.6M | ||
| Q2 24 | $10.1M | $474.3M | ||
| Q1 24 | $5.9M | $296.3M |
总债务RGSRXRX
| Q4 25 | $113.3M | $9.6M | ||
| Q3 25 | $111.3M | $11.9M | ||
| Q2 25 | $110.8M | $14.2M | ||
| Q1 25 | $112.0M | $16.4M | ||
| Q4 24 | $111.5M | $19.0M | ||
| Q3 24 | $95.2M | $20.5M | ||
| Q2 24 | $99.5M | $22.9M | ||
| Q1 24 | $179.7M | — |
股东权益RGSRXRX
| Q4 25 | $188.7M | $1.1B | ||
| Q3 25 | $187.6M | $1.0B | ||
| Q2 25 | $185.6M | $919.1M | ||
| Q1 25 | $68.6M | $933.9M | ||
| Q4 24 | $66.7M | $1.0B | ||
| Q3 24 | $56.4M | $524.6M | ||
| Q2 24 | $56.8M | $584.4M | ||
| Q1 24 | $-35.8M | $401.2M |
总资产RGSRXRX
| Q4 25 | $588.3M | $1.5B | ||
| Q3 25 | $592.1M | $1.4B | ||
| Q2 25 | $599.0M | $1.3B | ||
| Q1 25 | $511.2M | $1.3B | ||
| Q4 24 | $530.1M | $1.4B | ||
| Q3 24 | $508.9M | $726.5M | ||
| Q2 24 | $530.5M | $775.9M | ||
| Q1 24 | $543.7M | $557.8M |
负债/权益比RGSRXRX
| Q4 25 | 0.60× | 0.01× | ||
| Q3 25 | 0.59× | 0.01× | ||
| Q2 25 | 0.60× | 0.02× | ||
| Q1 25 | 1.63× | 0.02× | ||
| Q4 24 | 1.67× | 0.02× | ||
| Q3 24 | 1.69× | 0.04× | ||
| Q2 24 | 1.75× | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.7M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $891.0K | $-47.3M |
| 自由现金流率自由现金流/营收 | 1.6% | -133.1% |
| 资本支出强度资本支出/营收 | 1.4% | 3.5% |
| 现金转化率经营现金流/净利润 | 3.65× | — |
| 过去12个月自由现金流最近4个季度 | $14.9M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流RGSRXRX
| Q4 25 | $1.7M | $-46.1M | ||
| Q3 25 | $2.3M | $-117.4M | ||
| Q2 25 | $6.8M | $-76.4M | ||
| Q1 25 | $6.2M | $-132.0M | ||
| Q4 24 | $2.1M | $-115.4M | ||
| Q3 24 | $-1.3M | $-59.2M | ||
| Q2 24 | $5.1M | $-82.2M | ||
| Q1 24 | $-277.0K | $-102.3M |
自由现金流RGSRXRX
| Q4 25 | $891.0K | $-47.3M | ||
| Q3 25 | $1.9M | $-117.6M | ||
| Q2 25 | $6.2M | $-79.6M | ||
| Q1 25 | $5.9M | $-133.8M | ||
| Q4 24 | $1.7M | $-116.7M | ||
| Q3 24 | $-1.4M | $-63.8M | ||
| Q2 24 | $5.1M | $-83.4M | ||
| Q1 24 | $-326.0K | $-109.0M |
自由现金流率RGSRXRX
| Q4 25 | 1.6% | -133.1% | ||
| Q3 25 | 3.2% | -2272.5% | ||
| Q2 25 | 10.3% | -413.9% | ||
| Q1 25 | 10.3% | -907.4% | ||
| Q4 24 | 3.6% | -2567.7% | ||
| Q3 24 | -3.0% | -244.6% | ||
| Q2 24 | 10.3% | -578.5% | ||
| Q1 24 | -0.7% | -789.9% |
资本支出强度RGSRXRX
| Q4 25 | 1.4% | 3.5% | ||
| Q3 25 | 0.7% | 4.7% | ||
| Q2 25 | 0.9% | 16.4% | ||
| Q1 25 | 0.6% | 12.4% | ||
| Q4 24 | 0.9% | 28.6% | ||
| Q3 24 | 0.0% | 17.5% | ||
| Q2 24 | 0.0% | 8.2% | ||
| Q1 24 | 0.1% | 48.2% |
现金转化率RGSRXRX
| Q4 25 | 3.65× | — | ||
| Q3 25 | 1.68× | — | ||
| Q2 25 | 0.06× | — | ||
| Q1 25 | 24.80× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.06× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
RXRX
暂无分部数据
